BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

ApaTech Ltd Is The Recipient Of The 2004 Frost & Sullivan Entrepreneurial Company Award


10/19/2005 5:12:24 PM

LONDON, December 8 /PRNewswire/ -- ApaTech(TM) Ltd is the proud recipient of the 2004 Frost & Sullivan Entrepreneurial Company Award.

This award is based on its unique product solution, strategic alliances for distribution, relationships with key customers, level of positive-press coverage in the media and endorsements from industry experts.

ApaTech Limited, based in London, England, is a private orthopaedics company founded, in 2001, specialising in synthetic bone graft substitutes. Research and Intellectual Property from London and Cambridge Universities has resulted in a novel material, Pore-Si, that the company believes is the optimal scaffold for facilitating rapid and sustained bone ingrowth. Pore-Si is a new class of bone graft material that combines osseo-conductive and osseo-stimulatory activities.

Pore-Si is a novel calcium phosphate material in which phosphate groups have been selectively replaced by silicate groups. This creates a material that, in addition to the clinically proven interconnected macro and microporous structural properties of ApaTech's earlier products, enhances the deposition and function of the proteins involved in bone growth, thus inducing rapid formation of bone and improving the subsequent organisation and strength of the graft/host bone composite structure.

Pore-Si has recently gained both 510k approval from the FDA and CE mark approval. These regulatory approvals for Pore-Si provide surgeons with the opportunity to utilise a new generation bone graft material that is truly different from existing synthetic materials. Surgeons are increasingly seeking alternatives to autograft and allograft material but have been disappointed by several synthetic alternatives or the cost of BMP based products. Pore-Si will provide the surgeon with a new solution for their bone grafting needs.

Frost & Sullivan believe that ApaTech is poised for success in the highly competitive bone graft substitutes market.

Media contact ApaTech: Paul Moseley p: +44-207-882-7502 e: paul@apatech.com Media contact Frost & Sullivan: Katja Feick Corporate Communications p: +44-207-915-7856 e: katja.feick@frost.com

Frost & Sullivan

CONTACT: Media contact ApaTech: Paul Moseley, p: +44-207-882-7502, e:paul@apatech.com. Media contact Frost & Sullivan: Katja Feick,p: +44-207-915-7856, e: katja.feick@frost.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES